RadNet, Inc. (NASDAQ:RDNT) and the Kennedy Health System on 9 April announced a multi-faceted agreement to provide radiology services throughout southern New Jersey. RadNet Inc. (NASDAQ:RDNT) shares after opening at $4.08 moved to $4.71 on last trade day and at the end of the day closed at $4.41. Company price to sales ratio in past twelve months was calculated as 0.26 and price to cash ratio as 21.58. RadNet Inc. (NASDAQ:RDNT) showed a positive weekly performance of 17.29%.
Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem unloaded 29,500 shares of the company’s stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $74.71, for a total transaction of $2,203,945.00. Following the sale, the chief executive officer now directly owns 263,850 shares in the company, valued at approximately $19,712,234. Edwards Lifesciences Corp (NYSE:EW) shares advanced 11.00% in last trading session and ended the day on $81.00. EW return on equity ratio is recorded as 25.40% and its return on assets is 15.80%. Edwards Lifesciences Corp (NYSE:EW) yearly performance is -3.18%.
Akebia Therapeutics (NASDAQ:AKBA)’s stock had its “overweight” rating restated by research analysts at Morgan Stanley in a report released on Monday, ARN reports. Akebia Therapeutics Inc. (NASDAQ:AKBA) shares moved up 25.39% in last trading session and was closed at $21.14, while trading in range of $17.07 – $23.32. Akebia Therapeutics Inc. (NASDAQ:AKBA) year to date (YTD) performance is -20.79%.
Portola Pharmaceuticals Inc. (NASDAQ:PTLA) yesterday announced publication of the design and rationale of the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study in the March 2014 issue of the American Heart Journal. Betrixaban, the Company’s wholly-owned, oral, once-daily Factor Xa anticoagulant, is being evaluated in the only ongoing global, pivotal study of in-hospital and post-discharge prevention of venous thromboembolism (VTE), or blood clots, in patients who have been hospitalized for medical conditions, such as heart failure, stroke, infection and pulmonary disease. Portola Pharmaceuticals Inc. (NASDAQ:PTLA) weekly performance is -12.09%. On last trading day company shares ended up $22.10. Portola Pharmaceuticals Inc. (NASDAQ:PTLA) distance from 50-day simple moving average (SMA50) is -14.66%. Analysts mean target price for the company is $39.25.